{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:57:38Z","timestamp":1794650258581,"version":"4.9.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2025,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) prophylaxis is the standard of care after total joint arthroplasty. However, there have been changes in the prevalence of certain medication classes used by institutions over time driven by the literature and national clinical practice guidelines. The purpose of this study was to analyze the patterns of VTE medications over the past 10 years at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We identified 25,095 patients who underwent a primary total joint arthroplasty between 2012 and 2022. Medications for VTE prophylaxis included aspirin, warfarin, unfractioned heparin (UFH), low-molecular-weight heparin (LMWH), factor-Xa inhibitors (FXa), and antiplatelet agents different from aspirin and thrombin inhibitors. Tranexamic acid use was recorded. The rates of symptomatic VTE were calculated and categorized as deep vein thrombosis or pulmonary embolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Venous thromboembolism rates decreased from 1.1% in 2012 to 0.2% in 2022 and ranged between 0.4% and 1.2% during the ten-year period. Although VTE incidence decreased in the past 4 years, an isolated increase was noted in 2021(1%). In 2012, the use of aspirin, warfarin, FXa, and UFH were 52.1%, 30.7%, 0%, and 16.2%, respectively, whereas in 2022, the rates for the same medications were 83.3%, 0.3%, 10.4%, and 1.8%, respectively. The use of LMWH, thrombin inhibitors, and other antiplatelet agents had minimal variation, and none of these medications surpassed 5% during this period. The aspirin dose changed from 325 mg in 2012 (96.5%) to 81 mg in 2022 (98.8%). Similarly, TXA use increased from 30.8% in 2012 to 84.9% in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In the past 10 years, our institution has transitioned from warfarin, UFH, and high-dose aspirin to low-dose aspirin and FXa, exhibiting acceptably low deep vein thrombosis and diminishing pulmonary embolism rates during that time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-24-00507","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T17:00:22Z","timestamp":1730134822000},"page":"e673-e680","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Ten-Year Trends in Venous Thromboembolism Prophylaxis at a High-Volume Arthroplasty Center"],"prefix":"10.5435","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-5341","authenticated-orcid":false,"given":"Juan D.","family":"Lizcano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Tarabichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashas","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"R1-20250626","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.artd.2018.02.014","article-title":"What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients?","volume":"4","author":"Shahi","year":"2018","journal-title":"Arthroplast Today"},{"key":"R2-20250626","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archinte.159.5.445","article-title":"Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study","volume":"159","author":"Heit","year":"1999","journal-title":"Arch Intern Med"},{"key":"R3-20250626","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"R4-20250626","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American society of hematology 2019 guidelines for management of venous thromboembolism: Prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"R5-20250626","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1345\/aph.1R331","article-title":"Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: A comparison of the AAOS and ACCP guidelines with review of the evidence","volume":"47","author":"Stewart","year":"2013","journal-title":"Ann Pharmacother"},{"key":"R6-20250626","first-page":"3349","article-title":"Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty","volume":"87","author":"Tian","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"R7-20250626","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"R8-20250626","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamainternmed.2019.6108","article-title":"Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: A systematic review and meta-analysis of randomized clinical trials","volume":"180","author":"Matharu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"R9-20250626","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00402-005-0079-0","article-title":"Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients","volume":"126","author":"Senaran","year":"2006","journal-title":"Arch Orthop Trauma Surg"},{"key":"R10-20250626","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.artd.2021.06.015","article-title":"Time for an update? A look at current guidelines for venous thromboembolism prophylaxis after hip and knee arthroplasty and hip fracture","volume":"10","author":"Muscatelli","year":"2021","journal-title":"Arthroplast Today"},{"key":"R11-20250626","first-page":"255","article-title":"Comparison of switch-therapy modalities (enoxaparin to rivaroxaban\/dabigatran) and enoxaparin monotherapy after hip and knee replacement","volume":"49","author":"Ozler","year":"2015","journal-title":"Acta Orthop Traumatol Turc"},{"key":"R12-20250626","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1538-7836.2012.04635.x","article-title":"Bleeding risk in randomized controlled trials comparing warfarin and aspirin: A systematic review and meta\u2010analysis","volume":"10","author":"Warkentin","year":"2012","journal-title":"J Thromb Haemost JTH"},{"key":"R13-20250626","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamasurg.2016.4952","article-title":"Enhanced Recovery After Surgery: A Review","volume":"152","author":"Ljungqvist","year":"2017","journal-title":"JAMA Surg"},{"key":"R14-20250626","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2106\/00004623-199173040-00004","article-title":"Effects of epidural anesthesia on the incidence of deep-vein thrombosis after total knee arthroplasty","volume":"73","author":"Sharrock","year":"1991","journal-title":"J Bone Joint Surg Am"},{"key":"R15-20250626","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5435\/00124635-201112000-00008","article-title":"AAOS clinical practice guideline: Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont","year":"2011","journal-title":"The J Am Acad Ortho Surg"},{"key":"R16-20250626","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bja.2019.05.042","article-title":"Anaesthetic care of patients undergoing primary hip and knee arthroplasty: Consensus recommendations from the international consensus on anaesthesia-related outcomes after surgery group (ICAROS) based on a systematic review and meta-analysis","volume":"123","author":"Memtsoudis","year":"2019","journal-title":"Br J Anaesth"},{"key":"R17-20250626","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.arth.2019.03.057","article-title":"Changing patterns of anticoagulation after total hip arthroplasty in the United States: Frequency of deep vein thrombosis, pulmonary embolism, and complications with rivaroxaban and warfarin","volume":"34","author":"Glassberg","year":"2019","journal-title":"J Arthroplasty"},{"key":"R18-20250626","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.5435\/JAAOS-D-22-00708","article-title":"Trends of venous thromboembolism after total hip arthroplasty in the United States: Analysis from 2011 to 2019","volume":"31","author":"Agarwal","year":"2023","journal-title":"J Am Acad Orthopaedic Surgeons"},{"key":"R19-20250626","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"New Engl J Med"},{"key":"R20-20250626","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2106\/JBJS.21.01529","article-title":"Delegates*, TI-VH& K: Recommendations from the ICM-VTE: Hip & knee","volume":"104","year":"2022","journal-title":"JBJS"},{"key":"R21-20250626","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.arth.2016.02.074","article-title":"Aspirin is as effective as and safer than warfarin for patients at higher risk of venous thromboembolism undergoing total joint arthroplasty","volume":"31","author":"Huang","year":"2016","journal-title":"J Arthroplasty"},{"key":"R22-20250626","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2106\/JBJS.18.00335","article-title":"Potent anticoagulation does not reduce venous thromboembolism in high-risk patients","volume":"101","author":"Tan","year":"2019","journal-title":"J Bone Joint Surg Am Volume"},{"key":"R23-20250626","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/JXX.0000000000000159","article-title":"Evaluation of early wound leakage as a risk factor for prosthetic joint infection","volume":"31","author":"Kremers","year":"2019","journal-title":"J Am Assoc Nurse Pract"},{"key":"R24-20250626","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bja.2020.06.051","article-title":"Bleeding independently associated with mortality after noncardiac surgery (BIMS): An international prospective cohort study establishing diagnostic criteria and prognostic importance","volume":"126","author":"Roshanov","year":"2021","journal-title":"Br J Anaesth"},{"key":"R25-20250626","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1358863X21995566","article-title":"Venous thromboembolism in COVID-19: A systematic review and meta-analysis","volume":"26","author":"Kollias","year":"2021","journal-title":"Vasc Med"},{"key":"R26-20250626","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2106\/JBJS.16.00147","article-title":"Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: A preliminary analysis","volume":"99","author":"Parvizi","year":"2017","journal-title":"J Bone Joint Surg"},{"key":"R27-20250626","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jor.2021.02.005","article-title":"Low dose aspirin is effective in preventing venous thromboembolism in patients undergoing primary total knee arthroplasty","volume":"24","author":"Merkow","year":"2021","journal-title":"J Orthop"},{"key":"R28-20250626","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.arth.2021.02.007","article-title":"Low-dose vs regular-dose aspirin for venous thromboembolism prophylaxis in primary total joint arthroplasty","volume":"36","author":"Uvodich","year":"2021","journal-title":"J Arthroplasty"},{"key":"R29-20250626","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL randomized trial","volume":"328","author":"Sidhu","year":"2022","journal-title":"JAMA"},{"key":"R30-20250626","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"R31-20250626","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"New Engl J Med"},{"key":"R32-20250626","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CM9.0000000000001305","article-title":"Comparable efficacy of 100 mg aspirin twice daily and rivaroxaban for venous thromboembolism prophylaxis following primary total hip arthroplasty: A randomized controlled trial","volume":"134","author":"Ren","year":"2021","journal-title":"Chin Med J"},{"key":"R33-20250626","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fphar.2018.01370","article-title":"Cost-utility analysis of venous thromboembolism prophylaxis strategies for people undergoing elective total hip and total knee replacement surgeries in the English national health service","volume":"9","author":"Dawoud","year":"2018","journal-title":"Front Pharmacol"},{"key":"R34-20250626","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12891-015-0470-0","article-title":"Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: A systematic review of evidences in ten years","volume":"16","author":"Zhang","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"R35-20250626","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41598-022-26032-1","article-title":"Using machine learning to predict venous thromboembolism and major bleeding events following total joint arthroplasty","volume":"13","author":"Shohat","year":"2023","journal-title":"Sci Rep"},{"key":"R36-20250626","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1302\/0301-620X.100B1.BJJ-2017-0587.R1","article-title":"Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: Aspirin versus warfarin","volume":"100-B","author":"Goel","year":"2018","journal-title":"Bone Joint J"},{"key":"R37-20250626","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/BLO.0b013e318156c13f","article-title":"Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol","volume":"463","author":"Beksa\u00e7","year":"2007","journal-title":"Clin Orthop Relat Res"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-00507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:49:39Z","timestamp":1787669379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-00507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-24-00507","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"2024-05-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}